SEC Filing Summary: Catalyst Biosciences, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Catalyst Biosciences, Inc. (not Gyre Therapeutics, Inc.) on September 28, 2016, reporting events occurring on September 27, 2016. The filing serves as a Regulation FD disclosure regarding a corporate presentation delivered at the Ladenburg Thalmann 2016 Healthcare Conference in New York City.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a presentation event rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed within the text of this filing. The document solely references the delivery of a presentation (Exhibit 99.1) which is incorporated by reference but not included in the filing text provided.
Guidance, Outlook, and Risks
The filing explicitly states that the information contained in the presentation (Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, no specific guidance, outlook, or risk factors are articulated in the body of this 8-K. The presentation itself is not subject to the liabilities of that Section unless expressly incorporated by reference in another filing.
Investor Verification Checklist
- Verify the correct registrant name is Catalyst Biosciences, Inc., as the input metadata referenced Gyre Therapeutics, Inc.
- Review the attached Exhibit 99.1 (Corporate Presentation) for actual financial data, clinical updates, or strategic guidance, as the 8-K text contains none.
- Confirm whether the presentation materials have been incorporated by reference in subsequent filings to determine their legal standing.
- Note that the filing date (September 28, 2016) is one day after the event date (September 27, 2016).